Finally, evidence supporting the cardiovascular and renal benefits of SGLT2 inhibitors in patients with heart failure emerged only after the publication of large randomized control trials, such as DAPA-HF [44], EMPEROR-Reduced [45], and EMPEROR-Preserved [46], which likely explains the delayed implementation and lower use of these agents during earlier periods of the study. Here, SLC5A2 is linked to heart failure.